The Dow sank 600 points when news of coronavirus first began circulating.
Though it's regained some of those losses, the market may still hurt for a time.
However, there are a few biotech stocks charged with seeking out a vaccine that could pop over the next year.
In fact, our best biotech stock offers 182% upside potential.
The Dow sank 600 points when news of coronavirus first began circulating.
Though it's regained some of those losses, the market may still hurt for a time.
However, there are a few biotech stocks charged with seeking out a vaccine that could pop over the next year.
In fact, our best biotech stock offers 182% upside potential.
If you're a seasoned investor or just starting out, you might have heard of insider buying when it comes to a stock.
Insider buying can predict success in a stock.
And today, I'm going to show you a stock that's getting bought up by insides - meaning it's poised for a breakout.
Six analysts gave this stock an average 478% growth target.
I'm not as bullish as those guys, but my 72% target is still good reason to pay attention to this stock.
With recession indicators flashing, investors are flocking to 10-year bonds that have the annual upside of just 1.5%.
But there are still market-beating stocks out there – in fact, one of our picks expects 103% growth.
And that brings us to the biotech industry.
There are some big biotech stocks to own right now that could deliver double, even triple-digit upside in less than 12 months.
Biotech stocks have already netted investors huge gains.
In fact, we expect prices to skyrocket even further as the industry becomes a $727 billion juggernaut.
Biotech stocks have stalled in 2016 along with the broader markets, with the iShares Nasdaq Biotech ETF (Nasdaq: IBB) down 24.43% year to date.
Still, Money Morning Biotech Investing Specialist Ernie Tremblay says the sector will outperform in 2016. And he's pinpointed one foundational play that's already climbed 14% in the last five days.
But first, here's why biotech stocks are presenting a huge opportunity right now...
With a net worth of $12.6 billion, Patrick Soon-Shiong, MD, is the world's richest doctor, the richest American in the healthcare industry, and the 96th-richest person on the planet in 2015 according to Forbes.
And just in August, the 63-year-old became $1.1 billion richer -- from a move he'd made only eight months prior, according to Bloomberg...
Here's Soon-Shiong's story - plus five ways you can cash in with biotech profits of your own...
Today, we're recommending a biotech stock to buy that Money Morning Biotech Investing Specialist Ernie Tremblay says has a "nearly limitless" profit potential.
It's a medical device company with a revolutionary product that helps restore vision to people suffering from blindness.
Here's the revolutionary technology behind this biotech stock to buy...
Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has dipped nearly 5% in the last week after the company reported a Q2 earnings loss of $0.80. Analysts had been predicting a loss of $0.75 for the quarter.
In the past three months, TRIL stock has now dipped 16.4%, and the poor earnings report only stoked the fears of nervous investors.
Investors who know how to choose the best biotech stocks to buy can cash in. In the last twelve months alone, the Nasdaq Biotechnology Index ETF has outperformed the broader Nasdaq Composite by 25.5%. And the SPDR S&P Biotech ETF has outperformed the S&P 500 almost sevenfold.
Watch our three-minute video for five easy steps to picking the best biotech stocks to buy...
One of the last week's biggest IPOs, the food allergy company Aimmune Therapeutics Inc. (Nasdaq: AIMT), hit the market on Thursday, Aug. 6, and has already climbed more than 20%.
AIMT's early success underscores one of the best biotech stocks to buy that Money Morning Executive Editor Bill Patalon has been recommending all year.
Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has climbed 143% in 2015, and it's still one of the top biotech stocks to buy now.
You see, Trillium is at the forefront of a revolutionary treatment that could hold the key to curing various types of cancer.
Spending on cancer treatment has been skyrocketing globally. According to the IMS Institute of Health, spending on cancer topped $100 billion globally in 2014. That was a 10% increase from 2013.
That's why many biotech stocks tied to cancer treatments have seen triple-digit gains in the last two years.
On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company's stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.
Over the months since June 2013, when Clovis Oncology released positive trial data for both a lung cancer and a lymphoma drug, CLVS share value has soared 255%.
And just last summer, when Puma Biotechnology released positive results from a clinical trial of its breast cancer drug, neratanib, PBYI shares jumped 300% in a single session.
It's clear that investors can do very well with the right cancer drug.
But there, of course, is the rub: Finding the right cancer drug is not so easy.
Biotech stocks have seriously outperformed the markets in 2015, and our favorite biotech ETF has been one of the biggest winners.
In the last year, the Nasdaq Biotechnology Index has soared 48.3%. The Dow and S&P 500 are up just 7.3% and 8.6% in that time.
Here's our favorite biotech ETF to buy now...
Organovo Holdings Inc. (NYSE: ONVO) stock is up 12.7% this week after the company reported quarterly and fiscal year earnings on Tuesday.
For the quarter ending March 31, ONVO reported an earnings per share (EPS) loss of $0.10. That was below the consensus estimate of a $0.09 loss.
Here's what else investors need to know about ONVO stock now...
